readthroughSign in
Jul 10, 2026Weekly roundup

GSK posts bepirovirsen QT results; registers Mo-Rez ovarian, endometrial Phase 3 trials

Weekly roundup of GSK clinical trial registry updates spanning completed, recruiting, and not-yet-recruiting studies across hepatitis B, oncology, and cough programs.

GSK's registry activity this week centered on a completed cardiac safety readout, two new Phase 3 oncology trials, one recruiting Phase 2 oncology trial, and a withdrawn cough study.

  • A completed Phase 1 study evaluated the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo1 in healthy volunteers with hepatitis B as the underlying condition, with results posted and 46 participants enrolled.
  • GSK registered "BEHOLD-Ovarian03," a not-yet-recruiting Phase 3 trial of mocertatug rezetecan with or without bevacizumab compared to active observation with or without bevacizumab as maintenance treatment in participants with newly diagnosed FIGO Stage III/IV non-homologous recombination deficient ovarian cancer2, with an estimated enrollment of 720 participants.
  • GSK also registered "BEHOLD-Ovarian02," a not-yet-recruiting Phase 3 trial comparing mocertatug rezetecan in combination with bevacizumab against standard treatments in participants with platinum-sensitive ovarian cancer3, with an estimated enrollment of 690 participants.
  • A third not-yet-recruiting Phase 3 trial, "BEHOLD-Endometrial02," will test mocertatug rezetecan in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) as maintenance therapy in participants with advanced or recurrent endometrial cancer compared with immunotherapy alone4, with an estimated enrollment of 610 participants.
  • A Phase 2 trial of velzatinib (GSK6042981) is recruiting in Japan for GIST patients who have documented disease progression on or intolerance to imatinib, sunitinib, regorafenib, and pimitespib5, with an estimated enrollment of 24 participants.
  • A Phase 1 pharmacokinetic study of camlipixant formulation prototypes in healthy adults was withdrawn, with GSK citing the recent decision to cease further development of camlipixant in refractory chronic cough (RCC) based on Phase 3 program results6; enrollment was recorded as zero.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.